[go: up one dir, main page]

AR056586A1 - Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras - Google Patents

Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Info

Publication number
AR056586A1
AR056586A1 ARP060104701A ARP060104701A AR056586A1 AR 056586 A1 AR056586 A1 AR 056586A1 AR P060104701 A ARP060104701 A AR P060104701A AR P060104701 A ARP060104701 A AR P060104701A AR 056586 A1 AR056586 A1 AR 056586A1
Authority
AR
Argentina
Prior art keywords
proportions
potential
formulations containing
containing gamma
stabilized formulations
Prior art date
Application number
ARP060104701A
Other languages
English (en)
Inventor
Rivero Iraldo Bello
Saura Pedro Antonio Lopez
Vega Yanelda Garcia
Milian Hector Santana
Barreto Ana Aguilera
Angulo Lorenzo Anasagasti
Meireles Rolando Paez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR056586A1 publication Critical patent/AR056586A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulaciones farmacéuticas estables para ser aplicadas por vía parenteral (líquidas o liofilizadas), o topica (gel, ungüento o crema) que comprenden diferentes cantidades de los interferones recombinantes gamma y alfa en proporciones potenciadoras para el tratamiento de eventos patologicos que contemplan el crecimiento celular no fisiologico benigno o maligno de tejidos u organos.
ARP060104701A 2005-11-02 2006-10-27 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras AR056586A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050213A CU23432B6 (es) 2005-11-02 2005-11-02 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Publications (1)

Publication Number Publication Date
AR056586A1 true AR056586A1 (es) 2007-10-10

Family

ID=40269648

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104701A AR056586A1 (es) 2005-11-02 2006-10-27 Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras

Country Status (15)

Country Link
US (1) US8535657B2 (es)
EP (1) EP1958643B1 (es)
JP (1) JP5366551B2 (es)
KR (1) KR101363237B1 (es)
CN (2) CN104826094A (es)
AR (1) AR056586A1 (es)
AU (1) AU2006310918B2 (es)
BR (1) BRPI0618197B1 (es)
CA (1) CA2629895C (es)
CU (1) CU23432B6 (es)
ES (1) ES2619632T3 (es)
PT (1) PT1958643T (es)
RU (1) RU2403057C2 (es)
WO (1) WO2007051431A2 (es)
ZA (1) ZA200804256B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
ES2389760T3 (es) * 2010-04-14 2012-10-31 B. Braun Melsungen Ag Composición de acetaminofeno
RU2482871C2 (ru) * 2010-06-07 2013-05-27 Общество с ограниченной ответственностью "Центр Инновационных Технологий "БиоФарм" (ООО "ЦИТ "БиоФарм") Композиция для лечения вирусных заболеваний животных
MX352481B (es) 2010-07-22 2017-11-27 Reven Pharmaceuticals Inc Star Una solución de dipolo magnético estabilizado para tratar o aliviar enfermedades y mejorar el desempeño.
CN103619792A (zh) * 2011-04-27 2014-03-05 北岸大学健康系统 组合物和方法
RU2524651C1 (ru) * 2013-06-20 2014-07-27 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме раствора для инъекций и способ ее получения
CN104043110B (zh) * 2014-03-28 2016-05-04 上海交通大学 干扰素温敏水凝胶及其制备方法和应用
CN109819650A (zh) * 2017-09-25 2019-05-28 春布里泽·格奥尔基·格奥尔基耶维奇 具有抗病毒和抗细菌活性的热稳定组合物及其用途
IL275182B2 (en) 2017-12-07 2024-04-01 Reven Ip Holdco Llc Compositions and methods for the treatment of metabolic conditions
KR20220029657A (ko) * 2019-06-12 2022-03-08 리벤 아이피 홀드코 엘엘씨 암 환자의 결과를 향상시키기 위한 방법 및 조성물
CU20200029A7 (es) * 2020-05-20 2022-01-13 Ct Ingenieria Genetica Biotecnologia Composición farmacéutica para el tratamiento de enfermedades respiratorias de origen viral
CN114015758B (zh) * 2021-10-15 2022-06-24 无锡百泰克生物技术有限公司 一种冻干保护剂、荧光pcr检测试剂盒及冻干工艺
EP4423251A4 (en) * 2021-10-26 2026-01-07 Univ Georgia State Res Found Macrophages deficient in alpha syrup to treat cancer
CN115068592A (zh) * 2022-06-27 2022-09-20 长春生物制品研究所有限责任公司 开封后常温稳定的重组人干扰素α1b滴眼液及制备方法
CN115105584B (zh) * 2022-06-28 2023-03-31 长春生物制品研究所有限责任公司 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
DE3273597D1 (en) 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
ZA828580B (en) * 1981-12-23 1983-10-26 Schering Corp Interferon formulations
DE3381553D1 (de) 1982-10-25 1990-06-21 Genentech Inc Synergistische humaninterferonaktivitaet.
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
PT82249B (en) * 1985-03-25 1988-01-07 Schering Corp Process for preparing stable gamma-interferon formulations
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US5028422A (en) 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5002764A (en) 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
US5024833A (en) 1988-03-10 1991-06-18 Industrial Farmaceutica Serono Spa Combined interferon/antiestrogen therapy for treatment of breast cancer
ATE74517T1 (de) * 1987-01-20 1992-04-15 Schering Corp Behandlung von einigen leukaemien mit einer zusammensetzung von interferon-gamma und interferon-alpha.
US5190751A (en) 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
US4895716A (en) 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
IL88233A (en) 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
US5256410A (en) 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US5444064A (en) 1989-02-28 1995-08-22 Montefiore Medical Center Method of treating gastrointestinal malignancies
CA2024046A1 (en) * 1989-09-28 1991-03-29 Alberto Ferro Stabilized leukocyte-interferons
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
JPH07503851A (ja) 1992-02-10 1995-04-27 インターフェロン・サイエンシズ、インコーポレイテッド 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
GB9226729D0 (en) 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
CN1163264C (zh) * 1993-02-02 2004-08-25 爱克索马技术有限公司 改进的药物组合物
US5814640A (en) 1994-10-04 1998-09-29 Montefiore Medical Center Method of treating gastrointestinal malignancies
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
CA2453890A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Crystal and process for producing the same
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
US20060057106A1 (en) * 2002-12-13 2006-03-16 Chikamasa Yamashita Freeze-dried interferon-y composition for transpulmonary administration and inhalation system therefor
WO2004078207A1 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
JP2005162663A (ja) * 2003-12-02 2005-06-23 Asahi Denka Kogyo Kk 皮膚用基剤
US20050123575A1 (en) * 2003-12-03 2005-06-09 Eilon Asculai Spreadable compositions for topical use, an improved process of making same and methods of using same
EP2102748B1 (en) * 2006-12-22 2012-02-01 International Business Machines Corporation System and method for recovery of memory transactions

Also Published As

Publication number Publication date
EP1958643A2 (en) 2008-08-20
CU23432B6 (es) 2009-10-16
JP2009513682A (ja) 2009-04-02
BRPI0618197B1 (pt) 2021-06-29
EP1958643B1 (en) 2016-12-28
WO2007051431A2 (es) 2007-05-10
KR20080065684A (ko) 2008-07-14
RU2008121874A (ru) 2009-12-10
JP5366551B2 (ja) 2013-12-11
CN101351219A (zh) 2009-01-21
CN104826094A (zh) 2015-08-12
AU2006310918B2 (en) 2012-09-27
CA2629895A1 (en) 2007-05-10
AU2006310918A1 (en) 2007-05-10
US8535657B2 (en) 2013-09-17
BRPI0618197A2 (pt) 2013-01-08
PT1958643T (pt) 2017-03-23
ZA200804256B (en) 2009-05-27
ES2619632T3 (es) 2017-06-26
RU2403057C2 (ru) 2010-11-10
KR101363237B1 (ko) 2014-02-12
CA2629895C (en) 2016-08-30
US20090304628A1 (en) 2009-12-10
WO2007051431A3 (es) 2007-06-28

Similar Documents

Publication Publication Date Title
AR056586A1 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
Ryan et al. Isolation and culture of pulmonary artery endothelial cells
BRPI0615265A8 (pt) composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
CR9987A (es) Compuestos de lactama y métodos de uso de los mismos
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR9814698A (pt) Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
WO2006024492A3 (en) Medical implant provided with inhibitors of atp synthesis
ATE464055T1 (de) Topische zusammensetzungen mit phosphorylierten polyphenolen
SG144075A1 (en) Protein stabilization formulations
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
MX2010003291A (es) Supresion de tumores utilizando perfundido placentario humano y células destructoras naturales intermediarias derivadas de la placenta humana.
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
WO2005039490A3 (en) Methods and compositions for treating cancer
GT200900126A (es) Novedosos anticuerpos antiproliferacion
ATE353655T1 (de) Myo-inositol hexaphosphat zur topischen verwendung
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
ATE499098T1 (de) Verwendung von parp-1-hemmern
GT200600520A (es) Agentes antibacterianos
DE60007310D1 (de) Zusammensetzungen und methoden zur verhinderung des zelltods
CL2008003546A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii.
ATE413197T1 (de) Zusammensetzungen mit trialkanolamin-alkoxylat- puffer
MX2007004025A (es) Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.

Legal Events

Date Code Title Description
FC Refusal